In a comprehensive review, a strategic SWOT insight on Thermo Fisher Scientific Inc (TMO) was offered. Recently, Sheets Smith Wealth Management sold 1,974 shares of the company. Thermo Fisher Scientific's (TMO) Q1 2024 Earnings Call Transcript was released, and GUNN & Co made a new $253,000 investment in the company. The company also introduced a new CXCL10 testing service. Over the past five years, Thermo Fisher Scientific (TMO) shareholders have enjoyed a 17% CAGR. Still, the company noted some insider selling, with the CEO selling 10,000 shares. The company recently released its Q1 2024 earnings, beating expectations and offering a positive outlook. Shareholders who invested five years ago in Thermo Fisher Scientific (TMO) are up 114%. On a more sober note, Thermo Fisher Scientific stock has experienced some decline amidst a market uptick, and the company reported a cautious outlook on biotech demand for 2024. However, it has navigated economic headwinds well with a resilient 2023 performance. Recently the company extended the expiration of a tender offer for outstanding common shares and ADSs of Olink. The company maintains an active approach to its financial situation, recently authorizing $4 billion of share repurchases. Furthermore, Thermo Fisher Scientific expanded an ongoing strategic partnership with Flagship Pioneering. The company recently purchased Olink in a $3.1 billion deal.
Thermo Fisher Scientific TMO News Analytics from Wed, 06 Sep 2023 07:00:00 GMT to Mon, 06 May 2024 19:57:24 GMT - Rating 3 - Innovation 6 - Information 8 - Rumor -2
